stars 1 stars 2 stars 3

The world is seeing a rising allergy epidemic. This increasing prevalence in the Western world is closely linked to our hygienic lifestyle. A reduced exposure to bacteria during infancy delays activation of immunological defense mechanisms that protect from allergies. Dogs have followed in our footsteps over thousands of years, and many of the factors associated with increased allergy in humans is highly significant also for dogs. Allergy is considered one of the major diseases in dogs. It is estimated that over ten percent of all dogs suffer from allergies. In certain breeds, such as Bull Terriers, Boxers, and German Shepherds, the risk is significantly higher. Most common allergic disorders are atopic dermatitis (eczema) and food allergies, requiring life-long symptomatic treatment entailing high costs for the dog owner. Premune is developing a preventive technology that has the potential to change the view on canine allergy treatment. The discovery is based on fifteen years of detailed cohort studies where Premune has identified that infants exposed to a certain bacterial protein in the gut during the first weeks of life are protected from future allergy development. In animal trials the proteins ability to activate immunological tolerance has been confirmed. This product will be given as oral drops to the puppy during the first few weeks of life, in order to activate the immune system's natural defense against allergies.

Premune AB Questions

The Premune AB annual revenue was $405000 in 2026.

Premune AB is based in Stockholm, Stockholm.

The NAICS codes for Premune AB are [325, 32541, 3254, 32].

The SIC codes for Premune AB are [283, 28].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users